Navigation Links
Sinovac to Host Conference Call to Report 2009 Second Quarter Financial Results
Date:8/11/2009

BEIJING, Aug. 11 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Amex: SVA), a leading provider of vaccines in China, today announced that it will host a conference call on Wednesday, August 19, 2009 at 8:00 a.m. ET to review the Company's second quarter financial results for the period ended June 30, 2009 and provide an update on recent corporate developments.

To access the conference call, please dial 1-877-407-4018 (USA) or 1-201-689-8471 (international). A replay of the call will be available from 11:00 a.m. ET on August 19, 2009 to September 2, 2009 at midnight. To access the replay, please dial 1-877-660-6853 (USA) or 1-201-612-7415 (international) and reference the account number 3055 and the access code 330444.

A live audio webcast of the call will also be available from the Investors section on the corporate web site at http://www.sinovac.com . A webcast replay can be accessed on the corporate website beginning August 19, 2009 and the replay will remain available for 30 days.

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. Sinovac's commercialized vaccines include Healive(R) (hepatitis A), Bilive(R) (combined hepatitis A and B), and Anflu(R) (influenza). Panflu(TM), Sinovac's pandemic influenza vaccine (H5N1), has already been approved for government stockpiling. Sinovac is developing vaccines for Enterovirus 71, Universal Pandemic Influenza, Japanese encephalitis vaccine, and Human Rabies vaccine. Its wholly-owned subsidiary, Tangshan Yian, is conducting field trials for independently developed inactivated animal rabies vaccines.

    For more info
'/>"/>
SOURCE Sinovac Biotech Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Revised: Sinovac Provides Update on Clinical Trial for H1N1 Vaccine Trials
2. Sinovac Provides Update on Clinical Trial for H1N1 Vaccine Trials
3. Sinovac Initiates Dosing in Human Clinical Trial of Panflu for Pandemic Influenza A (H1N1)
4. Sinovac Adjourns 2008 Annual General Meeting
5. Sinovac Receives Chinas First Influenza A (H1N1) Vaccine Order
6. Sinovac Completes Construction of H1N1 Virus Seed Bank
7. Sinovac Begins the Production of Influenza A (H1N1) Vaccine
8. Chinas Vice Premier, Li Keqiang, Visits Sinovac to Inspect H1N1 Vaccine Production Preparation
9. Sinovac to Host Conference Call to Report First Quarter 2009 Financial Results
10. Sinovac Biotech Ltd. Files Annual Report on Form 20-F
11. Sinovac Initiates Preparatory Activities for Swine Flu Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... 20, 2014 The report, ... Oligos, Enzymes, Cloning kits), Technology (Bioinformatics, Nanotechnology, ... Pharmaceuticals, Biomaterials, Bioremediation) - Global Forecast to ... drivers, threats, opportunities, and challenges. , Browse ... spread through 185 pages and in-depth TOC ...
(Date:11/21/2014)... November 20, 2014 BlueInGreen, LLC ... Solutions, LLC (Pinnacle), and PCI, Inc., leading suppliers ... they have been selected to provide a new ... Arkansas Paul R. Noland Wastewater Treatment. The ... HyDOZ® gas dissolution technology, Pinnacle Ozone’s ...
(Date:11/21/2014)... 2014 Deep Research Report on ... professional and in-depth research report on the Sodium ... like its definition, classification, application, and industry chain ... covers the international market analysis, including China’s domestic ... US, Europe, Asia, China, Japan etc. regions) industry ...
(Date:11/21/2014)... Polaris Group announced today that the ... 1 trial of ADI-PEG 20 in combination with ... pleural mesothelioma (MPM) and non-squamous non-small cell lung ... ADI-PEG 20, both as monotherapy and in combination ... other indications, including breast cancer, melanomas, ovarian cancer, ...
Breaking Biology Technology:Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 2Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 3Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 4City of Fayetteville Leads Nation with Innovative Ozone Technology 2City of Fayetteville Leads Nation with Innovative Ozone Technology 3City of Fayetteville Leads Nation with Innovative Ozone Technology 4Sodium Ferrocyanide Market: Analysis for Global & China Regions Development Trends Available at DeepResearchReports.com 2Sodium Ferrocyanide Market: Analysis for Global & China Regions Development Trends Available at DeepResearchReports.com 3Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus Pemetrexed and Cisplatin in Malignant Pleural Mesothelioma And Non-Squamous Non-Small Cell Lung Carcinoma 2
... Nanotechnology (IBN) have uncovered new properties of imidazolium salts ... role in disease prevention and treatment. , The ... in the Journal of the American Chemical Society ... Angewandte Chemie International Edition , IBN researchers reported the ...
... 2 Transgenomic,Inc. (OTC Bulletin Board: TBIO) ... PWRM) today announced that Transgenomic has signed ... for Power3 Medical,s Neurodegenerative,Biomarkers, which include NuroPro(R), ... Transgenomic plans to offer NuroPro(R) in ...
... Mann Foundation for,Biomedical Engineering (AEMFBE), a philanthropic organization created ... at elite universities, designed to facilitate biomedical,product development for ... Web site ( http://www.mannfbe.org ). , ... , -- Overview ...
Cached Biology Technology:New uses for imidazolium salts in medicine and alternative energy 2New uses for imidazolium salts in medicine and alternative energy 3Transgenomic Signs Letter of Intent for an Agreement to Exclusive License With Option to Acquire Power3 Medical Products' Neurodegenerative Diagnostics 2Transgenomic Signs Letter of Intent for an Agreement to Exclusive License With Option to Acquire Power3 Medical Products' Neurodegenerative Diagnostics 3Transgenomic Signs Letter of Intent for an Agreement to Exclusive License With Option to Acquire Power3 Medical Products' Neurodegenerative Diagnostics 4Alfred Mann Foundation for Biomedical Engineering Launches New Web Site Designed to Help University Researchers Bring Biomedical Advances to Market 2
(Date:11/10/2014)... appearing on U.S. store shelves in early 2010, and ... The small packets can be tossed into a washing ... or powder. The convenience, though, has come with risks ... at Nationwide Children,s Hospital found that from 2012 through ... children younger than 6 years of age swallowing, inhaling, ...
(Date:11/7/2014)... November 6, 2014 Leading Biometric companies ... mobile security revolutionizing online transactions.  Companies in focus today are: ... (NYSE: BABA ), Google Inc. (NASDAQ: ... Inc. (NASDAQ: EBAY ) and MasterCard Inc. (NYSE: ... and NXTDW), a biometric authentication company focused on the growing ...
(Date:11/6/2014)... asset for a predator. Except when that predator runs so ... relative to its size, is the fastest creature on Earth. ... per second (at about five miles per hour). The fastest ... sprinting gold from the tiger beetle, a person would have ... beetle has a problem. At peak speeds, everything becomes a ...
Breaking Biology News(10 mins):Study finds laundry detergent pods, serious poisoning risk for children 2Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 2Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 3Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 4Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 5Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 6The tiger beetle: Too fast to see 2
... SALT LAKE CITY , Jan. 24, 2013 /PRNewswire-iReach/ ... start-up, has developed a new device for gesture ... a bracelet that uses accelerometers and machine learning algorithms ... the Amiigo device knows if users are using the ...
... , A team of researchers led by the UAB has found ... pelvis of the skeleton of a woman from the Roman era. ... tumour - formed by the remains of tissues or organs, which ... the small round mass, four teeth and a small piece of ...
... together researchers from across the world to develop new ... diseases and to connect research data in this area ... individually uncommon affect one person in every 17. ... they include genetic kidney diseases like nephrotic syndrome and ...
Cached Biology News:Amiigo Unveils Fitness Tracker That Knows What Exercise You're Performing 2Ovarian tumor, with teeth and a bone fragment inside, found in a Roman-age skeleton 2Eliminating rare diseases 2Eliminating rare diseases 3Eliminating rare diseases 4Eliminating rare diseases 5
... The enzyme glycerol 3-phosphate dehydrogenase ... phosphate (DHAP) and glycerol 3-phosphate, with ... increases significantly during differentiation of progenitor ... activity of this enzyme has been ...
... with an Affinity Chitin-binding Tag) utilizes the ... elements (termed inteins) to purify recombinant proteins ... 1 and 2). This system distinguishes itself ... ability to separate a recombinant protein from ...
... pET Host Strain Competent Cell Sets ... optimizing vector/host strain combinations The ... into E. coli is to ... can be prepared in the laboratory, greater ...
... EZ DNA Methylation Kit uses a simplified ... DNA methylation analysis. The kit is based ... place between cytosine and sodium bisulfite where ... DNA Methylation Kits innovative in-column desulphonation reaction ...
Biology Products: